Compare DX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DX | VERA |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | DX | VERA |
|---|---|---|
| Price | $14.03 | $44.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.33 | ★ $63.13 |
| AVG Volume (30 Days) | ★ 4.9M | 1.8M |
| Earning Date | 10-20-2025 | 11-05-2025 |
| Dividend Yield | ★ 14.54% | N/A |
| EPS Growth | ★ 35.65 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $230,447,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $134.14 | N/A |
| P/E Ratio | $8.46 | ★ N/A |
| Revenue Growth | ★ 87.09 | N/A |
| 52 Week Low | $10.79 | $18.53 |
| 52 Week High | $14.52 | $49.77 |
| Indicator | DX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 81.00 |
| Support Level | $13.80 | $32.66 |
| Resistance Level | $14.06 | $34.43 |
| Average True Range (ATR) | 0.18 | 2.64 |
| MACD | 0.02 | 1.68 |
| Stochastic Oscillator | 97.09 | 95.26 |
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.